Analytical Data
-
Gene name
bACE1
- Application
-
Alternative Names
bACE1；BACE；KIAA1149；Beta-secretase 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P56817
-
Expression Region
22-460aa
-
AA Sequence
TQHGIRLPLR SGLGGAPLGL RLPRETDEEP EEPGRRGSFV EMVDNLRGKS GQGYYVEMTV GSPPQTLNIL VDTGSSNFAV GAAPHPFLHR YYQRQLSSTY RDLRKGVYVP YTQGKWEGEL GTDLVSIPHG PNVTVRANIA AITESDKFFI NGSNWEGILG LAYAEIARPD DSLEPFFDSL VKQTHVPNLF SLQLCGAGFP LNQSEVLASV GGSMIIGGID HSLYTGSLWY TPIRREWYYE VIIVRVEING QDLKMDCKEY NYDKSIVDSG TTNLRLPKKV FEAAVKSIKA ASSTEKFPDG FWLGEQLVCW QAGTTPWNIF PVISLYLMGE VTNQSFRITI LPQQYLRPVE DVATSQDDCY KFAISQSSTG TVMGAVIMEG FYVVFDRARK RIGFAVSACH VHDEFRTAAV EGPFVTLDME DCGYNIPQTD ESTLMTIAY
-
Molecular Weight
50 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of bACE1 recombinant protein is rooted in the quest to understand the biology and function of the Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (bACE1), which plays a crucial role in the pathogenesis of Alzheimer’s disease. This aspartyl protease is involved in the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-beta peptides that aggregate to form plaques, a hallmark of Alzheimer's. Given its significant role in neurodegeneration, bACE1 has emerged as a key target for therapeutic interventions aimed at slowing or halting the progression of Alzheimer’s disease. Recombinant protein technology enables the production of bACE1 in a controlled environment, providing a reliable source for studying its enzymatic activity, structure, and interactions with potential inhibitors. Furthermore, by generating bACE1 in a recombinant system, researchers can carry out high-throughput screenings for novel drug candidates, elucidate the molecular mechanisms of action, and explore potential biomarkers associated with its activity. The relevance of bACE1 in neurobiology and pharmacology highlights the importance of continued research into this protein, aiming to develop effective strategies for Alzheimer's treatment and better understand its underlying pathology.
